Outlook Therapeutics said the agency has reversed course regarding its reformulated version of Avastin for the eye condition known as wet AMD.
After three FDA rejections dating back to 2023, Outlook Therapeutics said the agency has reversed course regarding its reformulated version of Avastin for the eye …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA - Outlook Therapeutics (NASDAQ:OTLK)
FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine
Presbyopia News
After prior FDA manufacturing snub, Gilead's hepatitis D med Hepcludex nabs US nod
EU and US advisers split over AstraZeneca breast cancer drug
Retina & Vitreous News
AstraZeneca breast cancer pill faces review delay from regulators
AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data
The FDA has proposed to withdraw its approval of avacopan for ANCA-associated vasculitis, alleging that employees of the original…
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
Outlook Therapeutics Inc. shares are trading higher Tuesday after the FDA granted its appeal in the ONS-5010 dispute resolution…
US regulators are willing to reconsider using a Phase 3 study of tab-cel as the basis for an approval, after previously rejecting…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
The FDA has delayed a decision on the approval of AstraZene | The FDA has delayed a decision on the approval of AstraZeneca’s…
